Abstract
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. Methods: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. Results: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ2 = 125.29, p < 0.001, χ2 = 9.08, p = 0.003, χ2 = 8.14, p = 0.004, χ2 = 19.48, p < 0.001, χ2 = 25.62, p < 0.001, and χ2 = 16.79, p < 0.001, respectively). Conclusions: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
References
1.
Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management
. (DSaRM). FDA Briefing Document. [cited 2020 Apr 1]. Available from https://www.fda.gov/media/121376/download2.
Kim
J
, Farchione
T
, Potter
A
, Chen
Q
, Temple
R
. Esketamine for treatment-resistant depression - first fda-approved antidepressant in a new class
. N Engl J Med
. 2019
Jul
;381
(1
):1
–4
.
[PubMed]
0028-47933.
Cristea
IA
, Naudet
F
. US Food and Drug Administration approval of esketamine and brexanolone
. Lancet Psychiatry
. 2019
Dec
;6
(12
):975
–7
.
[PubMed]
2215-03664.
Naudet
F
, Cristea
IA
. Approval of esketamine for treatment-resistant depression - Authors’ reply
. Lancet Psychiatry
. 2020
Mar
;7
(3
):235
–6
.
[PubMed]
2215-03665.
Turner
EH
. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
. Lancet Psychiatry
. 2019
Dec
;6
(12
):977
–9
.
[PubMed]
2215-03666.
Horowitz
MA
, Moncrieff
J
. Are we repeating mistakes of the past? A review of the evidence for esketamine
. Br J Psychiatry
. 2020
May
;•••
:1
–4
.
[PubMed]
0007-12507.
Schatzberg
AF
. A word to the wise about intranasal esketamine
. Am J Psychiatry
. 2019
Jun
;176
(6
):422
–4
.
[PubMed]
0002-953X8.
Aluisio
L
, Yieh
L
, Wajs
E
, DiBernardo
A
, Krystal
A
, Drevets
W
, et al. 142 withdrawal symptom assessment in an esketamine safety study in patients with treatment-resistant depression
. CNS Spectr
. 2020
Apr
;25
(2
):290
.
[PubMed]
1092-85299.
Doherty
T
, Wajs
E
, Melkote
R
, Miller
J
, Singh
JB
, Weber
MA
. Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program
. CNS Drugs
. 2020
Mar
;34
(3
):299
–310
.
[PubMed]
1172-704710.
Daly
EJ
, Trivedi
MH
, Janik
A
, Li
H
, Zhang
Y
, Li
X
, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial
. JAMA Psychiatry
. 2019
Jun
;76
(9
):893
–903
.
[PubMed]
2168-622X11.
Fedgchin
M
, Trivedi
M
, Daly
EJ
, Melkote
R
, Lane
R
, Lim
P
, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (transform-1)
. Int J Neuropsychopharmacol
. 2019
Oct
;22
(10
):616
–30
.
[PubMed]
1461-145712.
Ochs-Ross
R
, Daly
EJ
, Zhang
Y
, Lane
R
, Lim
P
, Morrison
RL
, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-transform-3
. Am J Geriatr Psychiatry
. 2020
Feb
;28
(2
):121
–41
.
[PubMed]
1064-748113.
Popova
V
, Daly
EJ
, Trivedi
M
, Cooper
K
, Lane
R
, Lim
P
, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study
. Am J Psychiatry
. 2019
Jun
;176
(6
):428
–38
.
[PubMed]
0002-953X14.
Gastaldon
C
, Papola
D
, Ostuzzi
G
, Barbui
C
. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Epidemiol Psychiatr Sci
. 2019
Dec
;29
:e79
.
[PubMed]
2045-796015.
Citrome
L
, DiBernardo
A
, Singh
J
. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2020
Jun
;271(228-38.16.
Hauben
M
, Bate
A
. Decision support methods for the detection of adverse events in post-marketing data
. Drug Discov Today
. 2009
Apr
;14
(7-8
):343
–57
.
[PubMed]
1359-644617.
18.
Schwartz
D
, Lellouch
J
. Explanatory and pragmatic attitudes in therapeutical trials
. J Chronic Dis
. 1967
Aug
;20
(8
):637
–48
.
[PubMed]
0021-968119.
US Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files.[cited 2020 May 1] Available from https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html
20.
Bate
A
, Evans
SJ
. Quantitative signal detection using spontaneous ADR reporting
. Pharmacoepidemiol Drug Saf
. 2009
Jun
;18
(6
):427
–36
.
[PubMed]
1053-856921.
Chavant
F
, Favrelière
S
, Lafay-Chebassier
C
, Plazanet
C
, Pérault-Pochat
MC
. Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database
. Br J Clin Pharmacol
. 2011
Dec
;72
(6
):898
–904
.
[PubMed]
0306-525122.
Raschi
E
, Poluzzi
E
, Salvo
F
, Pariente
A
, De Ponti
F
, Marchesini
G
, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems
. Nutr Metab Cardiovasc Dis
. 2018
Jun
;28
(6
):533
–42
.
[PubMed]
0939-475323.
Capellà
D
, Pedrós
C
, Vidal
X
, Laporte
JR
. Case-population studies in pharmacoepidemiology
. Drug Saf
. 2002
;25
(1
):7
–19
.
[PubMed]
0114-591624.
Almenoff
J
, Tonning
JM
, Gould
AL
, Szarfman
A
, Hauben
M
, Ouellet-Hellstrom
R
, et al. Perspectives on the use of data mining in pharmaco-vigilance
. Drug Saf
. 2005
;28
(11
):981
–1007
.
[PubMed]
0114-591625.
Sakaeda
T
, Tamon
A
, Kadoyama
K
, Okuno
Y
. Data mining of the public version of the FDA Adverse Event Reporting System
. Int J Med Sci
. 2013
Apr
;10
(7
):796
–803
.
[PubMed]
1449-190726.
Nakamura
M
. [Analysis of Spontaneously Reported Adverse Events]
. Yakugaku Zasshi
. 2016
;136
(4
):549
–56
.
[PubMed]
0031-690327.
Pace
ND
, Multani
JK
. On the reporting of odds ratios and risk ratios
. Nutrients
. 2018
Oct
;10
(10
):E1512
.
[PubMed]
2072-664328.
Evans
SJ
, Waller
PC
, Davis
S
. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
. Pharmacoepidemiol Drug Saf
. 2001
Oct-Nov
;10
(6
):483
–6
.
[PubMed]
1053-856929.
van Puijenbroek
EP
, Bate
A
, Leufkens
HG
, Lindquist
M
, Orre
R
, Egberts
AC
. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
. Pharmacoepidemiol Drug Saf
. 2002
Jan-Feb
;11
(1
):3
–10
.
[PubMed]
1053-856930.
Rothman
KJ
, Lanes
S
, Sacks
ST
. The reporting odds ratio and its advantages over the proportional reporting ratio
. Pharmacoepidemiol Drug Saf
. 2004
Aug
;13
(8
):519
–23
.
[PubMed]
1053-856931.
Bate
A
, Lindquist
M
, Edwards
IR
, Olsson
S
, Orre
R
, Lansner
A
, et al. A Bayesian neural network method for adverse drug reaction signal generation
. Eur J Clin Pharmacol
. 1998
Jun
;54
(4
):315
–21
.
[PubMed]
0031-697032.
Gatti
M
, Antonazzo
IC
, Diemberger
I
, De Ponti
F
, Raschi
E
. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
. Eur J Prev Cardiol
. 2020
Apr
;(Apr
):2047487320915663
.
[PubMed]
2047-487333.
Umetsu
R
, Abe
J
, Ueda
N
, Kato
Y
, Matsui
T
, Nakayama
Y
, et al. Association between selective serotonin reuptake inhibitor therapy and suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data
. Biol Pharm Bull
. 2015
;38
(11
):1689
–99
.
[PubMed]
0918-615834.
Rees
KE
, Chyou
TY
, Nishtala
PS
. A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
. Drug Saf
. 2020
Jun
;43
(6
):607
–9
.
[PubMed]
0114-591635.
Hoffman
KB
, Dimbil
M
, Erdman
CB
, Tatonetti
NP
, Overstreet
BM
. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010
. Drug Saf
. 2014
Apr
;37
(4
):283
–94
.
[PubMed]
0114-591636.
Weber
JC
. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford
KD
, Velo
GD
, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research
. New York
: Raven Press
; 1984
. pp. 1
–7
.37.
Pariente
A
, Gregoire
F
, Fourrier-Reglat
A
, Haramburu
F
, Moore
N
. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias
. Drug Saf
. 2007
;30
(10
):891
–8
.
[PubMed]
0114-591638.
Mathews
M
, Daly
EJ
, Popova
V
, Heerlein
K
, Canuso
C
, Drevets
WC
. Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
. Epidemiol Psychiatr Sci
. 2020
Apr
;29
:e124
.
[PubMed]
2045-796039.
Beck
K
, Hindley
G
, Borgan
F
, Ginestet
C
, McCutcheon
R
, Brugger
S
, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: A systematic review and meta-analysis
. JAMA Netw Open
. 2020
May
;3
(5
):e204693
–93
.
[PubMed]
2574-380540.
Wajs
E
, Aluisio
L
, Holder
R
, Daly
EJ
, Lane
R
, Lim
P
, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020
Apr
;81(3):19m1289141.
Fu
DJ
, Ionescu
DF
, Li
X
, Lane
R
, Lim
P
, Sanacora
G
, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: Double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020
May
;81(3):19m1319142.
Vickers-Smith
R
, Sun
J
, Charnigo
RJ
, Lofwall
MR
, Walsh
SL
, Havens
JR
. Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.
Drug Alcohol Depend. 2020
Jan
;206(107709. 43.
Lankenau
SE
, Sanders
B
, Bloom
JJ
, Hathazi
D
. Towards an explanation of subjective ketamine experiences among young injection drug users
. Addict Res Theory
. 2008
;16
(3
):273
–87
.
[PubMed]
1606-635944.
Caddy
C
, Amit
BH
, McCloud
TL
, Rendell
JM
, Furukawa
TA
, McShane
R
, et al. Ketamine and other glutamate receptor modulators for depression in adults
. Cochrane Database Syst Rev
. 2015
Sep
;(9
):CD011612
.
[PubMed]
1469-493X45.
Cosci
F
, Chouinard
G
. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications
. Psychother Psychosom
. 2020
Apr
;(Apr
):1
–24
.
[PubMed]
1423-034846.
Zhu
W
, Ding
Z
, Zhang
Y
, Shi
J
, Hashimoto
K
, Lu
L
. Risks associated with misuse of ketamine as a rapid-acting antidepressant
. Neurosci Bull
. 2016
Dec
;32
(6
):557
–64
.
[PubMed]
1673-706747.
Dubovsky
SL
. What is new about new antidepressants?
Psychother Psychosom
. 2018
;87
(3
):129
–39
.
[PubMed]
0033-319048.
Longpré-Poirier
C
, Desbeaumes Jodoin
V
, Miron
JP
, Lespérance
P
. “Remote Monitoring of Intranasal Ketamine Self-Administration as Maintenance Therapy in Treatment-Resistant Depression (TRD): A Novel Strategy for Vulnerable and At-Risk Populations to COVID-19?”
Am J Geriatr Psychiatry
. 2020
Aug
;28
(8
):892
–3
.
[PubMed]
1064-748149.
Chen
WY
, Huang
MC
, Lin
SK
. Gender differences in subjective discontinuation symptoms associated with ketamine use
. Subst Abuse Treat Prev Policy
. 2014
Sep
;9
(1
):39
.
[PubMed]
1747-597X50.
Lee
CJ
, Do
BR
, Kim
JK
, Yoon
YD
. Pentobarbital and ketamine suppress serum concentrations of sex hormones in the female rat
. J Anesth
. 2000
;14
(4
):187
–90
.
[PubMed]
0913-866851.
Zarate
CA
Jr, Brutsche
N
, Laje
G
, Luckenbaugh
DA
, Venkata
SL
, Ramamoorthy
A
, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression
. Biol Psychiatry
. 2012
Aug
;72
(4
):331
–8
.
[PubMed]
0006-322352.
Carmona-Huerta
J
, Castiello-de Obeso
S
, Ramírez-Palomino
J
, Duran-Gutiérrez
R
, Cardona-Muller
D
, Grover-Paez
F
, et al. Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification
. BMC Psychiatry
. 2019
Feb
;19
(1
):78
.
[PubMed]
1471-244X53.
K L. Hobden PSS
, B W. LeRoy, D Lindsay. An empirical examination of the prevalence and predictors of polypharmacy in individuals with dual diagnoses. International Journal of Disability, Community and Rehabilitation. 2013
;12(1)54.
van Hunsel
F
, van Puijenbroek
E
, de Jong-van den Berg
L
, van Grootheest
K
. Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins
. Pharmacoepidemiol Drug Saf
. 2010
Jan
;19
(1
):26
–32
.
[PubMed]
1053-856955.
Kaur
U
, Pathak
BK
, Singh
A
, Chakrabarti
SS
. Esketamine: a glimmer of hope in treatment-resistant depression
. Eur Arch Psychiatry Clin Neurosci
. 2019
Nov
;•••
:
[PubMed]
0940-133456.
Gastaldon
C
, Papola
D
, Ostuzzi
G
, Barbui
C
. Esketamine clinical trials: reply to Maju et al
. Epidemiol Psychiatr Sci
. 2020
Apr
;29
:e122
.
[PubMed]
2045-796057.
de Leon
J
, Ruan
CJ
, Schoretsanitis
G
, De Las Cuevas
C
. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology
. Psychother Psychosom
. 2020
;89
(4
):200
–14
.
[PubMed]
0033-319058.
Carvalho
AF
, Sharma
MS
, Brunoni
AR
, Vieta
E
, Fava
GA
. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature
. Psychother Psychosom
. 2016
;85
(5
):270
–88
.
[PubMed]
0033-319059.
Fava
GA
. Rational use of antidepressant drugs
. Psychother Psychosom
. 2014
;83
(4
):197
–204
.
[PubMed]
0033-319060.
Approval package for spravato nasal spray [package insert], Titusville, NJ: Janssen Pharmaceuticals Inc.
2019
.© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
